Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

Amondys 45 Gets DMD Nod From FDA

 
• By Alaric DeArment

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

MUSCULAR DYSTROPHY words written on label tag with medicine,syringe,keyboard and stethoscope
Sarepta's Amondys 45 won accelerated FDA approval for DMD patients ameable to exon 45 skipping • Source: Shutterstock

More from Business

More from Scrip